Company Filing History:
Years Active: 2017
Title: The Innovative Contributions of Dan Denney
Introduction
Dan Denney is a notable inventor based in Fremont, CA (US). He has made significant contributions to the field of immunotherapy, particularly in predicting patient responsiveness to treatment for B cell lineage malignancies. His work has the potential to enhance the effectiveness of cancer therapies and improve patient outcomes.
Latest Patents
Dan Denney holds a patent titled "Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy." This patent focuses on predictive biomarkers that identify patients suffering from immunoglobulin positive (Ig) B lineage malignancies who are responsive to active immunotherapy. The patent reveals that the sequence of the immunogen plays a crucial role in patient responsiveness. Specifically, an immunogen with a low number of tyrosine residues in the CDR1 regions of the immunogen heavy and light chains is predictive of a positive anti-tumor response. Conversely, a high number of CDR1 tyrosine residues indicates a low anti-tumor response. This innovative approach could significantly impact the future of cancer treatment.
Career Highlights
Dan Denney is affiliated with Leland Stanford Junior University, where he continues to advance research in immunotherapy. His work is characterized by a commitment to improving therapeutic strategies for cancer patients. With a patent portfolio that includes one patent, Denney is recognized for his contributions to the scientific community.
Collaborations
Dan has collaborated with esteemed colleagues such as Arash Ash Alizadeh and Ronald Levy. These partnerships have fostered a collaborative environment that enhances research and innovation in the field of immunotherapy.
Conclusion
Dan Denney's innovative work in predicting the responsiveness of B cell lineage malignancies to immunotherapy exemplifies the impact of research on cancer treatment. His contributions are paving the way for more effective therapies and better patient care.